GlobeNewswire

Centrient Pharmaceuticals Initiates Patent Litigation in India Against Dalas Biotech Limited

Share

Centrient Pharmaceuticals (“Centrient”), the global leader in the production and commercialisation of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed a lawsuit against Dalas Biotech Limited (“Dalas”) for patent infringement.

ROTTERDAM, Holland, May 01, 2019 (GLOBE NEWSWIRE) -- Centrient Pharmaceuticals announced that on April 25, 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 247301. This patent, which is owned by Centrient, describes an enzymatic process for preparing amoxicillin trihydrate having a low free water content. By its complaint, Centrient seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use,  sale in India and exportation out of India of Dalas’ active pharmaceutical ingredient containing amoxicillin trihydrate produced by a process that amounts to infringement of Indian Patent No. 247301.

Karl Rotthier, CEO at Centrient said: “After having previously filed patent litigation against Sinopharm Weiqida Pharmaceuticals for patent infringement in India, and the Court granting an injunction since April 2017, Centrient shows that it will continue to rigorously enforce its IP assets worldwide against any additional potential infringers in India or abroad.”

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals. We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. 

With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our 2700 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. 

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm. 

Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

BOURBON: Press release - Update on the search operations of the Bourbon Rhode crew12.10.2019 09:00:00 CESTPress release

Marseilles, October 12, 2019 Update on the search operations of the Bourbon Rhode crew Following the report of a possible distress flare on the night of Sunday 6 to Monday October 7, the CROSS French West Indies-Guyana (Regional Operational Centre for Surveillance and Rescue) dispatched 4 ships to search the area, with the support of an overflight by the US Coast Guards aircraft. Over the past week, search has been intense and extensive to try to detect a sign after on the one hand, the report of this potential distress flare and on the other hand, the satellite photo obtained from the European Maritime Safety Agency (EMSA). These new searches have unfortunately been unsuccessful. As a whole, search operations have not found any trace of life or life rafts for more than 10 days now despite measures of exceptional magnitude. As a reminder, search and rescue operations have been going on for 16 days, with the sinking of the ship taking place on September 26 as it faced hurricane Lorenzo.

Agfa-Gevaert: Publication of a transparency notification (AOC) – Regulated information11.10.2019 17:40:00 CESTPress release

(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – October 11, 2019 – 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: Active Ownership Capital S.à.r.l. has announced on April 18, 2019, that it managed a stake in Agfa-Gevaert as per April 12, 2019 of 23,069,853 voting rights or 13.42% (denominator is 171,851,042). On this date, AOC Value S.A.S. individually held 13,402,784 voting rights or 7.80%. On April 12, 2019, Active Ownership Fund SICAV-FIS SCS contributed 4,535,000 shares already held by it in Agfa-Gevaert NV to AOC Technology S.A.S., as a result of which AOC Technology S.A.S. directly holds 9,667,069 voting rights or 5.63% of Agfa-

DNO ASA: Mandatory Notification of Trade11.10.2019 16:56:00 CESTPress release

Oslo, 11 October 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,900,000 own shares at an average price of NOK 13.0887 per share. Following this transaction, DNO holds 73,200,000 own shares. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

PRF: Unaudited preliminary consolidated turnover of AS PRFoods in the 3rd quarter of 201911.10.2019 16:28:00 CESTPress release

PRFoods’ unaudited preliminary consolidated turnover in 3Q 2019 (i.e. 1Q of the fiscal year 2019/2020) amounted to EUR 19.32 million euros (19.40 million euros in 3Q 2018). The third quarter of 2019 was characterized by a general decline of raw material prices for fish products, resulting in lower prices for both fish and fish fillets, and smoked products. Despite the ca 5% decrease in the price of the Group’s main products, we managed to increase the share of other fish products and keep the total turnover largely at the level of last year. The turnover of other fish products increased by 1.01 million euros, whereas turnover from smoked fish product group and raw fish and fillets’ product group decreased by 0.54 million euros and 0.48 million euros, respectively. The Group’s revenue structure has changed both in regard to product groups as well as client groups compared to the same period a year ago. The share of other fish products increased by 5.30 percentage points. The share of ra

Conditions for Inflation-linked auctions11.10.2019 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Inflation-linked Government Bonds, 2019-10-18 Maturity date Loan ISIN code Coupon Volume, SEK million 2026-06-01 3112 SE0008014062 0.125 % 250 +/- 250 2028-12-01 3104 SE0000556599 3.50 % 250 +/- 250 Settlement date 2019-10-22 Bids have to be entered by 10.00 on OCT 18, 2019 Highest permitted bid volume: 250 SEK million Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON OCT 18, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

Conditions for Riksbank Bid Procedures Sek Bonds11.10.2019 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2019-10-17 Maturity date Loan ISIN code Coupon Volume, SEK million 2023-11-13 1057 SE0004869071 1.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/- 250 Settlement date 2019-10-21 Bids have to be entered by 10.00 on OCT 17, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1057 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON OCT 17, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se